Stay up-to-date on the latest research and scientific progress related to Genzada Pharmaceuticals and our pipeline of drug candidates.
May 12, 2022
“This is a significant and exciting achievement for our company,” said Chief Operating Officer Cameron West, MD. “Our Phase 1 study demonstrated that 6.02 has a favorable safety profile and provided clinical benefit to patients. Based on this data, in addition to the robust preclinical data, we are optimistic that 6.02 in combination with capecitabine…
Read More
March 20, 2019
Genzada Pharmaceuticals USA Inc. announced today that the first patient enrolled in its Phase 1 clinical trial for the oral therapeutic GZ17-6.02 received the first dose this week at HonorHealth Research Institute in Scottsdale, Ariz.
Read More
November 20, 2018
More than 600,000 people are expected to die from cancer this year, according to the National Cancer Institute. However, one Kansas company in Sterling is working to decrease that number and ultimately find a cure.
Read More